Small cell lung cancer broadly consists of four molecular subtypes, three of which are driven by expression of proteins called transcription factors. Targeting these transcription factors has been a long-held goal, yet currently there are no medicines that target them directly. Rather, patients today receive standard-of-care treatment consisting of chemotherapy and immunotherapy. Within a year, … Read more
In trial after clinical trial, metastatic colorectal cancer has been largely undeterred by immune checkpoint inhibitors. Although these drugs have shown effectiveness in Hodgkin lymphoma, lung cancer, bladder cancer, kidney cancer, and nearly a dozen other malignancies, their track record against colorectal cancer has been lackluster, particularly for patients with the most common subtype of … Read more
What is TIL (tumor-infiltrating lymphocyte) therapy? Tumor-infiltrating lymphocyte, or TIL, therapy uses a patient’s own immune system T cells to fight cancer. The therapy involves removing T cells from a piece of the patient’s tumor – where the T cells have congregated after being alerted to the cancer – growing them outside the body, then … Read more
What is BPDCN? Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare but aggressive blood cancer that can affect the skin, blood, and bone marrow. It has characteristics similar to leukemias and lymphomas, but almost always first appears as lesions in the skin. What are the treatment options for BPDCN? The first drug that was … Read more